Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dimethyl fumarate - Biogen

Drug Profile

Dimethyl fumarate - Biogen

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 30 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Pulmonary arterial hypertension
  • No development reported Rheumatoid arthritis
  • Discontinued Psoriasis

Most Recent Events

  • 14 Jan 2019 Phase-III clinical trials in Multiple sclerosis (In children, In adolescents) in Estonia (PO)
  • 10 Oct 2018 Pooled integrated efficacy and safety data from the phase III DEFINE, CONFIRM, and ENDORSE studies presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2018)
  • 10 Oct 2018 Updated efficacy data from the phase III ENDORSE trial presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top